COLUMBUS, Ohio – The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) announces the following awards, honors, grants and more that were recently given to the organization, teams or individuals:

Eisfeld nominated to serve on National Clinical Trials Network committee

Ann-Kathrin Eisfeld, MD, associate professor in the Division of Hematology at Ohio State and director of the Clara D. Bloomfield Center for Leukemia Outcomes Research at the OSUCCC – James, was nominated to serve on the National Clinical Trials Network Core Correlative Sciences Committee (NCTN-CCSC), which is part of the National Cancer Institute’s Cancer Therapy Evaluation Program (CTEP). The committee reviews and prioritizes research proposals requesting the use of banked, non-reserved biospecimens collected from NCTN clinical trials for use in correlative science studies. It also ensures optimal use of these specimens. Dr. Eisfeld, who also in the Leukemia and Hematologic Malignancies Program at the OSUCCC – James, focuses her research on understanding the genomic basis of acute myeloid leukemia (AML).

Dr. Eisfeld is a 2024 recipient of a $75,000 Real-World Data Impact Award from the American Cancer Society and Flatiron Health Inc. The award is designed to accelerate cancer research that informs public health and public policy with the goal of improving clinical practice. This award also gives Dr. Eisfeld access to Flatiron AML data (worth about $500,000) for a year.

ASH 2024 Abstract Achievement Award recipients listed

Four cancer research trainees at the OSUCCC – James received abstract achievement awards from the American Society of Hematology (ASH) at its 2024 annual meeting and exposition held Dec.7-10 in San Diego. ASH presents these awards to trainees with the highest-scoring abstracts. The four awardees, their faculty mentors and their abstract titles are:

• Anthony Mansour (Mentor: Jennifer Woyach, MD), “Outcomes of Patients with Chronic Lymphocytic Leukemia Discontinuing Bruton Tyrosine Kinase Inhibitors Due to Adverse Effects”
• Britten Gordon (Mentor: Jennifer Woyach, MD), “Genome-Wide CRISPR/Cas9 Knockout Screen Reveals Novel LP-168 (Rocbrutinib) Combinations Targeting BCL-2 Protein Members for Chronic Lymphocytic Leukemia”
• Betsy Pray, DVM, PhD, (Mentor: Lapo Alinari, MD, PhD), “Targeting the DNA Damage Response through TBL1X in Mantle Cell Lymphoma”
• Zachary Braunstein (Mentor: Jonathan Brammer, MD), “Survival and Therapeutic Outcomes in T-Cell Prolymphocytic Leukemia (T-PLL): A Collaborative Multi-Center Study Cohort”

Caputo lands travel grant to attend hematologic international meeting

Jean Caputo, APRN-CNP, a certified nurse practitioner in the Division of Hematology at Ohio State, was selected to receive an American Society for Transplantation and Cellular Therapy (ACTCT) Travel Grant to defray the costs of attending the 2025 Tandem Meeting of the ACTCT and the Center for International Blood and Marrow Transplant Research (CIBMTR) to be held Feb. 12-15 in Hawaii. The Tandem Meeting will provide a full scientific program that addresses the timeliest issues in hematopoietic cell transplantation, cellular therapy and gene therapy.

MEDIA CONTACT: Amanda Harper | OSUCCC - Media Relations
614-685-5420